Search

Your search keyword '"Akpek, Gorgun"' showing total 231 results
Start Over Author "Akpek, Gorgun"
231 results on '"Akpek, Gorgun"'

1. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups

Author

Scott, Emma C, Hari, Parameswaran, Kumar, Sathish, Fraser, Raphael, Davila, Omar, Shah, Nina, Gale, Robert Peter, Diaz, Miguel Angel, Agrawal, Vaibhav, Cornell, Robert F, Ganguly, Siddhartha, Akpek, Gorgun, Freytes, Cesar, Hashmi, Shahrukh, Malek, Ehsan, Kamble, Rammurti T, Lazarus, Hillard, Solh, Melhem, Usmani, Saad Z, Kanate, Abraham S, Saad, Ayman, Chhabra, Saurabh, Gergis, Usama, Cerny, Jan, Kyle, Robert A, Lee, Cindy, Kindwall-Keller, Tamila, Assal, Amer, Hildebrandt, Gerhard C, Holmberg, Leona, Maziarz, Richard T, Nishihori, Taiga, Seo, Sachiko, Kumar, Shaji, Mark, Tomer, and D'Souza, Anita

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Transplantation, Rare Diseases, Hematology, Cancer, Clinical Research, Adult, Aged, Cell Differentiation, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Staging, Prospective Studies, Transplantation, Autologous, International staging system, Revised international staging system, Staging system comparison, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

The Revised International Staging System (R-ISS) and the International Myeloma Working Group 2014 (IMWG 2014) are newer staging systems used to prognosticate multiple myeloma (MM) outcomes. We hypothesized that these would provide better prognostic differentiation for newly diagnosed multiple myeloma (MM) compared with ISS. We analyzed the Center for International Blood and Marrow Transplant Research database from 2008 to 2014 to compare the 3 systems (N = 628) among newly diagnosed MM patients undergoing upfront autologous hematopoietic cell transplantation (AHCT). The median follow-up of survivors was 48 (range, 3 to 99) months. The R-ISS provided the greatest differentiation between survival curves for each stage (for overall survival [OS], the differentiation was 1.74 using the R-ISS, 1.58 using ISS, and 1.60 using the IMWG 2014) . Univariate analyses at 3 years for OS showed R-ISS I at 88% (95% confidence interval [CI], 83% to 93%), II at 75% (95% CI, 70% to 80%), and III at 56% (95% CI, 3% to 69%; P < .001). An integrated Brier score function demonstrated the R-ISS had the best prediction for PFS, though all systems had similar prediction for OS. Among available systems, the R-ISS is the most optimal among available prognostic tools for newly diagnosed MM undergoing AHCT. We recommend that serum lactate dehydrogenase and cytogenetic data be performed on every MM patient at diagnosis to allow accurate prognostication.

Published
2018

2. Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A Center for International Blood and Marrow Transplant Research Analysis

Author

Paulson, Kristjan, Brazauskas, Ruta, Khera, Nandita, He, Naya, Majhail, Navneet, Akpek, Gorgun, Aljurf, Mahmoud, Buchbinder, David, Burns, Linda, Beattie, Sara, Freytes, Cesar, Garcia, Anne, Gajewski, James, Hahn, Theresa, Knight, Jennifer, LeMaistre, Charles, Lazarus, Hillard, Szwajcer, David, Seftel, Matthew, Wirk, Baldeep, Wood, William, and Saber, Wael

Published
2019
Full Text
View/download PDF

3. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia

Author

Hogan, William, Battiwalla, Minoo, Copelan, Edward, Hildebrandt, Gerhard, Ganguly, Sid, Majhail, Navneet, Woolfrey, Ann, Nivison-Smith, Ian, Hertzberg, Mark, Diaz, Miguel Angel, Jakubowski, Ann, Ustun, Celalettin, Yong, Agnes, Freytes, Cesar, DeFilipp, Zachariah, Inamoto, Yoshi, Cahn, Jean-Yves, Savani, Bipin, Yared, Jean, Bajel, Ashish, Bacher, Ulrike, Uy, Geoffrey, Rizzieri, David, Wieduwilt, Matthew, Schultz, Kirk, Grunwald, Michael, Kamble, Rammurti, Qayed, Muna, Brammer, Jonathan, Ballen, Karen, Khera, Nandita, Schouten, Harry, Bierings, Marc, Kanakry, Christopher, Wood, William Allen, Saad, Ayman, Savoie, Lynn, Hamilton, Betty Ky, Aljurf, Mahmoud, Vij, Ravi, Pawarode, Attaphol, Olsson, Richard, Wirk, B. Mona, Beitinjaneh, Amer, Seo, Sachiko, Cerny, Jan, Akpek, Gorgun, Norkin, Maxim, Nishihori, Taiga, Lazaryan, Aleksandr, Sabloff, Mitchell, Kebriaei, Partow, Anasetti, Claudio, Zhang, Mei-Jie, Wang, Hai-Lin, Aldoss, Ibrahim, de Lima, Marcos, Khoury, H. Jean, Sandmaier, Brenda M., Horowitz, Mary M., Artz, Andrew, Bejanyan, Nelli, Ciurea, Stefan, Lazarus, Hillard M., Gale, Robert Peter, Litzow, Mark, Bredeson, Christopher, Seftel, Matthew D., Pulsipher, Michael A., Boelens, Jaap-Jan, Alvarnas, Joseph, Champlin, Richard, Forman, Stephen, Pullarkat, Vinod, Weisdorf, Daniel, and Marks, David I.

Published
2018
Full Text
View/download PDF

4. Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes

Author

Gerds, Aaron T., Woo Ahn, Kwang, Hu, Zhen-Huan, Abdel-Azim, Hisham, Akpek, Gorgun, Aljurf, Mahmoud, Ballen, Karen K., Beitinjaneh, Amer, Bacher, Ulrike, Cahn, Jean-Yves, Chhabra, Saurabh, Cutler, Corey, Daly, Andrew, DeFilipp, Zachariah, Gale, Robert Peter, Gergis, Usama, Grunwald, Michael R., Hale, Gregory A., Hamilton, Betty Ky, Jagasia, Madan, Kamble, Rammurti T., Kindwall-Keller, Tamila, Nishihori, Taiga, Olsson, Richard F., Ramanathan, Muthalagu, Saad, Ayman A., Solh, Melhem, Ustun, Celalettin, Valcárcel, David, Warlick, Erica, Wirk, Baldeep M., Kalaycio, Matt, Alyea, Edwin, Popat, Uday, Sobecks, Ronald, and Saber, Wael

Published
2017
Full Text
View/download PDF

5. Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia

Author

Liu, Hien Duong, Ahn, Kwang Woo, Hu, Zhen-Huan, Hamadani, Mehdi, Nishihori, Taiga, Wirk, Baldeep, Beitinjaneh, Amer, Rizzieri, David, Grunwald, Michael R., Sabloff, Mitchell, Olsson, Richard F., Bajel, Ashish, Bredeson, Christopher, Daly, Andrew, Inamoto, Yoshihiro, Majhail, Navneet, Saad, Ayman, Gupta, Vikas, Gerds, Aaron, Malone, Adriana, Tallman, Martin, Reshef, Ran, Marks, David I., Copelan, Edward, Gergis, Usama, Savoie, Mary Lynn, Ustun, Celalettin, Litzow, Mark R., Cahn, Jean-Yves, Kindwall-Keller, Tamila, Akpek, Gorgun, Savani, Bipin N., Aljurf, Mahmoud, Rowe, Jacob M., Wiernik, Peter H., Hsu, Jack W., Cortes, Jorge, Kalaycio, Matt, Maziarz, Richard, Sobecks, Ronald, Popat, Uday, Alyea, Edwin, and Saber, Wael

Published
2017
Full Text
View/download PDF

6. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma

Author

Cornell, Robert F., D'Souza, Anita, Kassim, Adetola A., Costa, Luciano J., Innis-Shelton, Racquel D., Zhang, Mei-Jie, Huang, Jiaxing, Abidi, Muneer, Aiello, Jack, Akpek, Gorgun, Bashey, Asad, Bashir, Qaiser, Cerny, Jan, Comenzo, Raymond, Diaz, Miguel Angel, Freytes, César, Gale, Robert Peter, Ganguly, Siddhartha, Hamadani, Mehdi, Hashmi, Shahrukh, Holmberg, Leona, Hossain, Nasheed, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed, Kindwall-Keller, Tamila, Kyle, Robert, Kumar, Shaji, Lazarus, Hillard, Lee, Cindy, Maiolino, Angelo, Marks, David I., Meehan, Kenneth, Mikhael, Joe, Nath, Rajneesh, Nishihori, Taiga, Olsson, Richard F., Ramanathan, Muthalagu, Saad, Ayman, Seo, Sachiko, Usmani, Saad, Vesole, David, Vij, Ravi, Vogl, Dan, Wirk, Baldeep M., Yared, Jean, Krishnan, Amrita, Mark, Tomer, Nieto, Yago, and Hari, Parameswaran

Published
2017
Full Text
View/download PDF

7. Data from Rapid Immune Recovery and Graft-versus-Host Disease–like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells

Author

Rapoport, Aaron P., primary, Stadtmauer, Edward A., primary, Aqui, Nicole, primary, Vogl, Dan, primary, Chew, Anne, primary, Fang, Hong-Bin, primary, Janofsky, Stephen, primary, Yager, Kelly, primary, Veloso, Elizabeth, primary, Zheng, Zhaohui, primary, Milliron, Todd, primary, Westphal, Sandra, primary, Cotte, Julio, primary, Huynh, Hong, primary, Cannon, Andrea, primary, Yanovich, Saul, primary, Akpek, Gorgun, primary, Tan, Ming, primary, Virts, Kristen, primary, Ruehle, Kathleen, primary, Harris, Carolynn, primary, Philip, Sunita, primary, Vonderheide, Robert H., primary, Levine, Bruce L., primary, and June, Carl H., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Table 1 from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

Author

Rapoport, Aaron P., primary, Aqui, Nicole A., primary, Stadtmauer, Edward A., primary, Vogl, Dan T., primary, Xu, Yin Yan, primary, Kalos, Michael, primary, Cai, Ling, primary, Fang, Hong-Bin, primary, Weiss, Brendan M., primary, Badros, Ashraf, primary, Yanovich, Saul, primary, Akpek, Gorgun, primary, Tsao, Patricia, primary, Cross, Alan, primary, Mann, Dean, primary, Philip, Sunita, primary, Kerr, Naseem, primary, Brennan, Andrea, primary, Zheng, Zhaohui, primary, Ruehle, Kathleen, primary, Milliron, Todd, primary, Strome, Scott E., primary, Salazar, Andres M., primary, Levine, Bruce L., primary, and June, Carl H., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Data from Rapid Immune Recovery and Graft-versus-Host Disease–like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells

Author

Rapoport, Aaron P., primary, Stadtmauer, Edward A., primary, Aqui, Nicole, primary, Vogl, Dan, primary, Chew, Anne, primary, Fang, Hong-Bin, primary, Janofsky, Stephen, primary, Yager, Kelly, primary, Veloso, Elizabeth, primary, Zheng, Zhaohui, primary, Milliron, Todd, primary, Westphal, Sandra, primary, Cotte, Julio, primary, Huynh, Hong, primary, Cannon, Andrea, primary, Yanovich, Saul, primary, Akpek, Gorgun, primary, Tan, Ming, primary, Virts, Kristen, primary, Ruehle, Kathleen, primary, Harris, Carolynn, primary, Philip, Sunita, primary, Vonderheide, Robert H., primary, Levine, Bruce L., primary, and June, Carl H., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 2 from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

Author

Rapoport, Aaron P., primary, Aqui, Nicole A., primary, Stadtmauer, Edward A., primary, Vogl, Dan T., primary, Xu, Yin Yan, primary, Kalos, Michael, primary, Cai, Ling, primary, Fang, Hong-Bin, primary, Weiss, Brendan M., primary, Badros, Ashraf, primary, Yanovich, Saul, primary, Akpek, Gorgun, primary, Tsao, Patricia, primary, Cross, Alan, primary, Mann, Dean, primary, Philip, Sunita, primary, Kerr, Naseem, primary, Brennan, Andrea, primary, Zheng, Zhaohui, primary, Ruehle, Kathleen, primary, Milliron, Todd, primary, Strome, Scott E., primary, Salazar, Andres M., primary, Levine, Bruce L., primary, and June, Carl H., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure Legends from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

Author

Rapoport, Aaron P., primary, Aqui, Nicole A., primary, Stadtmauer, Edward A., primary, Vogl, Dan T., primary, Xu, Yin Yan, primary, Kalos, Michael, primary, Cai, Ling, primary, Fang, Hong-Bin, primary, Weiss, Brendan M., primary, Badros, Ashraf, primary, Yanovich, Saul, primary, Akpek, Gorgun, primary, Tsao, Patricia, primary, Cross, Alan, primary, Mann, Dean, primary, Philip, Sunita, primary, Kerr, Naseem, primary, Brennan, Andrea, primary, Zheng, Zhaohui, primary, Ruehle, Kathleen, primary, Milliron, Todd, primary, Strome, Scott E., primary, Salazar, Andres M., primary, Levine, Bruce L., primary, and June, Carl H., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 3 from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

Author

Rapoport, Aaron P., primary, Aqui, Nicole A., primary, Stadtmauer, Edward A., primary, Vogl, Dan T., primary, Xu, Yin Yan, primary, Kalos, Michael, primary, Cai, Ling, primary, Fang, Hong-Bin, primary, Weiss, Brendan M., primary, Badros, Ashraf, primary, Yanovich, Saul, primary, Akpek, Gorgun, primary, Tsao, Patricia, primary, Cross, Alan, primary, Mann, Dean, primary, Philip, Sunita, primary, Kerr, Naseem, primary, Brennan, Andrea, primary, Zheng, Zhaohui, primary, Ruehle, Kathleen, primary, Milliron, Todd, primary, Strome, Scott E., primary, Salazar, Andres M., primary, Levine, Bruce L., primary, and June, Carl H., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 1 from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

Author

Rapoport, Aaron P., primary, Aqui, Nicole A., primary, Stadtmauer, Edward A., primary, Vogl, Dan T., primary, Xu, Yin Yan, primary, Kalos, Michael, primary, Cai, Ling, primary, Fang, Hong-Bin, primary, Weiss, Brendan M., primary, Badros, Ashraf, primary, Yanovich, Saul, primary, Akpek, Gorgun, primary, Tsao, Patricia, primary, Cross, Alan, primary, Mann, Dean, primary, Philip, Sunita, primary, Kerr, Naseem, primary, Brennan, Andrea, primary, Zheng, Zhaohui, primary, Ruehle, Kathleen, primary, Milliron, Todd, primary, Strome, Scott E., primary, Salazar, Andres M., primary, Levine, Bruce L., primary, and June, Carl H., primary

Published
2023
Full Text
View/download PDF

14. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial

Author

Alvarnas, Joseph C., Le Rademacher, Jennifer, Wang, Yanli, Little, Richard F., Akpek, Gorgun, Ayala, Ernesto, Devine, Steven, Baiocchi, Robert, Lozanski, Gerard, Kaplan, Lawrence, Noy, Ariela, Popat, Uday, Hsu, Jack, Morris, Lawrence E., Jr, Thompson, Jason, Horowitz, Mary M., Mendizabal, Adam, Levine, Alexandra, Krishnan, Amrita, Forman, Stephen J., Navarro, Willis H., and Ambinder, Richard

Published
2016
Full Text
View/download PDF

15. Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers

Author

Shaw, Bronwen E., Logan, Brent R., Kiefer, Deidre M., Chitphakdithai, Pintip, Pedersen, Tanya L., Abdel-Azim, Hisham, Abidi, Muneer H., Akpek, Gorgun, Diaz, Miguel A., Artz, Andrew S., Dandoy, Christopher, Gajewski, James L., Hematti, Peiman, Kamble, Rammurti T., Kasow, Kimberley A., Lazarus, Hillard M., Liesveld, Jane L., Majhail, Navneet S., O’Donnell, Paul V., Olsson, Richard F., Savani, Bipin N., Schears, Raquel M., Stroncek, David F., Switzer, Galen E., Williams, Eric P., Wingard, John R., Wirk, Baldeep M., Confer, Dennis L., and Pulsipher, Michael A.

Published
2015
Full Text
View/download PDF

17. Race and Ethnicity Influences Collection of Granulocyte Colony–Stimulating Factor–Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a Center for International Blood and Marrow Transplant Research Analysis

Author

Hsu, Jack W., Wingard, John R., Logan, Brent R., Chitphakdithai, Pintip, Akpek, Gorgun, Anderlini, Paolo, Artz, Andrew S., Bredeson, Chris, Goldstein, Steven, Hale, Gregory, Hematti, Peiman, Joshi, Sarita, Kamble, Rammurti T., Lazarus, Hillard M., O'Donnell, Paul V., Pulsipher, Michael A., Savani, Bipin N., Schears, Raquel M., Shaw, Bronwen E., and Confer, Dennis L.

Published
2015
Full Text
View/download PDF

18. Integrated Genomic and Transcriptomic Analysis Provides Molecular Characterization of Distinct Clonal Evolution Pathways during Follicular Lymphoma Transformation

Author

Almog, Nava, primary, Novokreshchenova, Anna, additional, Smirnova, Sofia, additional, Brown, Jessica H., additional, Kotlov, Nikita, additional, Meerson, Mark, additional, Anosov, Ilya, additional, Akpek, Gorgun, additional, Ayrons, Keith, additional, Fowler, Nathan H., additional, and Ferguson, Kevin, additional

Published
2022
Full Text
View/download PDF

19. Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission

Author

Warlick, Erica D., Paulson, Kristjan, Brazauskas, Ruta, Zhong, Xiaobo, Miller, Alan M., Camitta, Bruce M., George, Biju, Savani, Bipin N., Ustun, Celalettin, Marks, David I., Waller, Edmund K., Baron, Frédéric, Freytes, César O., Socie, Gérard, Akpek, Gorgun, Schouten, Harry C., Lazarus, Hillard M., Horwitz, Edwin M., Koreth, John, Cahn, Jean-Yves, Bornhauser, Martin, Seftel, Matthew, Cairo, Mitchell S., Laughlin, Mary J., Sabloff, Mitchell, Ringdén, Olle, Gale, Robert Peter, Kamble, Rammurti T., Vij, Ravi, Gergis, Usama, Mathews, Vikram, Saber, Wael, Chen, Yi-Bin, Liesveld, Jane L., Cutler, Corey S., Ghobadi, Armin, Uy, Geoffrey L., Eapen, Mary, Weisdorf, Daniel J., and Litzow, Mark R.

Published
2014
Full Text
View/download PDF

20. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

Author

Warlick, Erica, Ahn, Kwang Woo, Pedersen, Tanya L., Artz, Andrew, de Lima, Marcos, Pulsipher, Michael, Akpek, Gorgun, Aljurf, Mahmoud, Cahn, Jean-Yves, Cairo, Mitchell, Chen, Yi-Bin, Cooper, Brenda, Deol, Abhinav, Giralt, Sergio, Gupta, Vikas, Khoury, H. Jean, Kohrt, Holbrook, Lazarus, Hillard M., Lewis, Ian, Olsson, Richard, Pidala, Joseph, Savani, Bipin N., Seftel, Matthew, Socié, Gerard, Tallman, Martin, Ustun, Celaettin, Vij, Ravi, Vindeløv, Lars, and Weisdorf, Daniel

Published
2012
Full Text
View/download PDF

22. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma

Author

Rapoport, Aaron P., Aqui, Nicole A., Stadtmauer, Edward A., Vogl, Dan T., Fang, Hong-Bin, Cai, Ling, Janofsky, Stephen, Chew, Anne, Storek, Jan, Akpek, Gorgun, Badros, Ashraf, Yanovich, Saul, Tan, Ming T., Veloso, Elizabeth, Pasetti, Marcela F., Cross, Alan, Philip, Sunita, Murphy, Heather, Bhagat, Rita, Zheng, Zhaohui, Milliron, Todd, Cotte, Julio, Cannon, Andrea, Levine, Bruce L., Vonderheide, Robert H., and June, Carl H.

Published
2011
Full Text
View/download PDF

23. Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial

Author

Shindiapina, Polina, primary, Pietrzak, Maciej, additional, Seweryn, Michal, additional, McLaughlin, Eric, additional, Zhang, Xiaoli, additional, Makowski, Mat, additional, Ahmed, Elshafa Hassan, additional, Schlotter, Sarah, additional, Pearson, Rebecca, additional, Kitzler, Rhonda, additional, Mozhenkova, Anna, additional, Le-Rademacher, Jennifer, additional, Little, Richard F., additional, Akpek, Gorgun, additional, Ayala, Ernesto, additional, Devine, Steven M., additional, Kaplan, Lawrence D., additional, Noy, Ariela, additional, Popat, Uday R., additional, Hsu, Jack W., additional, Morris, Lawrence E., additional, Mendizabal, Adam M., additional, Krishnan, Amrita, additional, Wachsman, William, additional, Williams, Nita, additional, Sharma, Nidhi, additional, Hofmeister, Craig C., additional, Forman, Stephen J., additional, Navarro, Willis H., additional, Alvarnas, Joseph C., additional, Ambinder, Richard F., additional, Lozanski, Gerard, additional, and Baiocchi, Robert A., additional

Published
2021
Full Text
View/download PDF

24. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

Author

Hu, Bei, Lin, Xiao, Lee, Hans C., Huang, Xuelin, Tidwell, Rebecca S. Slack, Ahn, Kwang Woo, Hu, Zhen-Huan, Jabbour, Elias, Verstovsek, Srdan, Ravandi, Farhad, Garcia-Manero, Guillermo, Kharfan-Dabaja, Mohamed A., Hossain, Nasheed M., Marks, David I., Kamble, Rammuriti T., Inamoto, Yoshihiro, Kindwall-Keller, Tamila, Saad, Ayman, Litzow, Mark R., Savani, Bipin N., Hale, Gregory A., Bacher, Ulrike, Gerds, Aaron T., Liesveld, Jane L., Ustun, Celalettin, Olsson, Richard, Daly, Andrew, Grunwald, Michael R., Solh, Melhem, DeFilipp, Zachariah, Aljurf, Mahmoud, Wirk, Baldeep, Akpek, Gorgun, Nishihori, Taiga, Cerny, Jan, Seo, Sachiko, Hsu, Jack W., Champlin, Richard, de Lima, Marcos, Alyea, Edwin, Popat, Uday, Sobecks, Ronald, Scott, Bart L., Kantarjian, Hagop, Cortes, Jorge, Saber, Wael, Hu, Bei, Lin, Xiao, Lee, Hans C., Huang, Xuelin, Tidwell, Rebecca S. Slack, Ahn, Kwang Woo, Hu, Zhen-Huan, Jabbour, Elias, Verstovsek, Srdan, Ravandi, Farhad, Garcia-Manero, Guillermo, Kharfan-Dabaja, Mohamed A., Hossain, Nasheed M., Marks, David I., Kamble, Rammuriti T., Inamoto, Yoshihiro, Kindwall-Keller, Tamila, Saad, Ayman, Litzow, Mark R., Savani, Bipin N., Hale, Gregory A., Bacher, Ulrike, Gerds, Aaron T., Liesveld, Jane L., Ustun, Celalettin, Olsson, Richard, Daly, Andrew, Grunwald, Michael R., Solh, Melhem, DeFilipp, Zachariah, Aljurf, Mahmoud, Wirk, Baldeep, Akpek, Gorgun, Nishihori, Taiga, Cerny, Jan, Seo, Sachiko, Hsu, Jack W., Champlin, Richard, de Lima, Marcos, Alyea, Edwin, Popat, Uday, Sobecks, Ronald, Scott, Bart L., Kantarjian, Hagop, Cortes, Jorge, and Saber, Wael

Abstract

While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed with CP CML based on timing of alloHCT or continuation of TKI in various settings: CP1 CML, CP2 + [after transformation to accelerated phase (AP) or blast phase (BP)], AP, or BP. Non-transplant cohort included single-institution patients initiating TKI and switched TKI due to failure. CIBMTR transplant cohort included CML patients who underwent HLA sibling matched (MRD) or unrelated donor (MUD) alloHCT. AlloHCT appeared to shorten survival in CP1 CML with overall mortality hazard ratio (HR) for alloHCT of 2.4 (95% CI 1.2-4.9;p = .02). In BP CML, there was a trend toward higher survival with alloHCT; HR = 0.7 (0.5-1.1;p = .099). AlloHCT in CP2 + [HR = 2.0 (0.8-4.9),p = .13] and AP [HR = 1.1 (0.6-2.1);p = .80] is less clear and should be determined on a case-by-case basis.

Published
2020
Full Text
View/download PDF

25. Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report

Author

Pavletic, Steven Z., Martin, Paul, Lee, Stephanie J., Mitchell, Sandra, Jacobsohn, David, Cowen, Edward W., Turner, Maria L., Akpek, Gorgun, Gilman, Andrew, McDonald, George, Schubert, Mark, Berger, Ann, Bross, Peter, Chien, Jason W., Couriel, Daniel, Dunn, J.P., Fall-Dickson, Jane, Farrell, Ann, Flowers, Mary E.D., Greinix, Hildegard, Hirschfeld, Steven, Gerber, Lynn, Kim, Stella, Knobler, Robert, Lachenbruch, Peter A., Miller, Frederick W., Mittleman, Barbara, Papadopoulos, Esperanza, Parsons, Susan K., Przepiorka, Donna, Robinson, Michael, Ward, Michael, Reeve, Bryce, Rider, Lisa G., Shulman, Howard, Schultz, Kirk R., Weisdorf, Daniel, and Vogelsang, Georgia B.

Published
2006
Full Text
View/download PDF

27. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

Author

Hu, Bei, primary, Lin, Xiao, additional, Lee, Hans C., additional, Huang, Xuelin, additional, Tidwell, Rebecca S. Slack, additional, Ahn, Kwang Woo, additional, Hu, Zhen-Huan, additional, Jabbour, Elias, additional, Verstovsek, Srdan, additional, Ravandi, Farhad, additional, Garcia-Manero, Guillermo, additional, Kharfan-Dabaja, Mohamed A., additional, Hossain, Nasheed M., additional, Marks, David I., additional, Kamble, Rammuriti T., additional, Inamoto, Yoshihiro, additional, Kindwall-Keller, Tamila, additional, Saad, Ayman, additional, Litzow, Mark R., additional, Savani, Bipin N., additional, Hale, Gregory A., additional, Bacher, Ulrike, additional, Gerds, Aaron T., additional, Liesveld, Jane L., additional, Ustun, Celalettin, additional, Olsson, Richard F., additional, Daly, Andrew, additional, Grunwald, Michael R., additional, Solh, Melhem, additional, DeFilipp, Zachariah, additional, Aljurf, Mahmoud, additional, Wirk, Baldeep, additional, Akpek, Gorgun, additional, Nishihori, Taiga, additional, Cerny, Jan, additional, Seo, Sachiko, additional, Hsu, Jack W., additional, Champlin, Richard, additional, de Lima, Marcos, additional, Alyea, Edwin, additional, Popat, Uday, additional, Sobecks, Ronald, additional, Scott, Bart L., additional, Kantarjian, Hagop, additional, Cortes, Jorge, additional, and Saber, Wael, additional

Published
2020
Full Text
View/download PDF

28. Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Author

Shindiapina, Polina, primary, Pietrzak, Maciej, additional, Seweryn, Michal, additional, McLaughlin, Eric, additional, Zhang, Xiaoli, additional, Makowski, Mateusz, additional, Lyberger, Justin, additional, Chang, Hsiaochi, additional, Ahmed, Elshafa Hassan, additional, Prouty, Alexander, additional, Pearson, Rebecca, additional, Kitzler, Rhonda, additional, Le-Rademacher, Jennifer, additional, Little, Richard F., additional, Akpek, Gorgun, additional, Ayala, Ernesto, additional, Devine, Steven, additional, Noy, Ariela, additional, Kaplan, Lawrence D, additional, Popat, Uday, additional, Hsu, Jack W., additional, Morris, Lawrence E, additional, Mendizabal, Adam M., additional, Hofmeister, Craig C, additional, Wachsman, William, additional, Forman, Stephen J, additional, Navarro, Willis H., additional, Alvarnas, Joseph C., additional, Ambinder, Richard F., additional, Behbehani, Gregory K., additional, Lozanski, Gerard, additional, and Baiocchi, Robert A, additional

Published
2019
Full Text
View/download PDF

29. Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A CIBMTR Analysis

Author

Paulson, Kristjan, Brazauskas, Ruta, Khera, Nandita, He, Naya, Majhail, Navneet, Akpek, Gorgun, Aljurf, Mahmoud, Buchbinder, David, Burns, Linda, Beattie, Sara, Freytes, Cesar, Garcia, Anne, Gajewski, James, Hahn, Theresa, Knight, Jennifer, LeMaistre, Charles, Lazarus, Hillard, Szwajcer, David, Seftel, Matthew, Wirk, Baldeep, Wood, William, and Saber, Wael

Subjects
Male, Transplantation Conditioning, hemic and lymphatic diseases, Hematopoietic Stem Cell Transplantation, Humans, Transplantation, Homologous, Female, Article
Abstract

Allogeneic hematopoietic cell transplantation (alloHCT) is offered in a limited number of medical centers and is associated with significant direct and indirect costs. The degree to which social and geographic barriers reduce access to alloHCT is unknown. Data from the Surveillance, Epidemiology and End Results Program (SEER) and the Center for International Blood and Marrow Transplant Research (CIBMTR) were integrated to determine the rate of unrelated donor (URD) alloHCT for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) performed between 2000 and 2010 in the 612 counties covered by SEER. The total incidence of AML, ALL, and MDS was determined using SEER, and the number of alloHCTs performed in the same time period and geographic area were determined using the CIBMTR database. We then determined which sociodemographic attributes influenced the rate of alloHCT (rural/urban status, median family size, percentage of residents below the poverty line, and percentage of minority race). In the entire cohort, higher levels of poverty were associated with lower rates of alloHCT (estimated rate ratio [ERR], .86 for a 10% increase in the percentage of the population below the poverty line; P.01), whereas rural location was not (ERR, .87; P = .11). Thus, patients from areas with higher poverty rates diagnosed with ALL, AML, and MDS are less likely patients from wealthier counties to undergo URD alloHCT. There is need to better understand the reasons for this disparity and to encourage policy and advocacy efforts to improve access to medical care for all.

Published
2019

33. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups

Author

Scott, Emma C., primary, Hari, Parameswaran, additional, Kumar, Sathish, additional, Fraser, Raphael, additional, Davila, Omar, additional, Shah, Nina, additional, Gale, Robert Peter, additional, Diaz, Miguel Angel, additional, Agrawal, Vaibhav, additional, Cornell, Robert F., additional, Ganguly, Siddhartha, additional, Akpek, Gorgun, additional, Freytes, Cesar, additional, Hashmi, Shahrukh, additional, Malek, Ehsan, additional, Kamble, Rammurti T., additional, Lazarus, Hillard, additional, Solh, Melhem, additional, Usmani, Saad Z., additional, Kanate, Abraham S., additional, Saad, Ayman, additional, Chhabra, Saurabh, additional, Gergis, Usama, additional, Cerny, Jan, additional, Kyle, Robert A., additional, Lee, Cindy, additional, Kindwall-Keller, Tamila, additional, Assal, Amer, additional, Hildebrandt, Gerhard C., additional, Holmberg, Leona, additional, Maziarz, Richard T., additional, Nishihori, Taiga, additional, Seo, Sachiko, additional, Kumar, Shaji, additional, Mark, Tomer, additional, and D'Souza, Anita, additional

Published
2018
Full Text
View/download PDF

35. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma

Author

Radivoyevitch, Tomas, Dean, Robert M., Shaw, Bronwen E., Brazauskas, Ruta, Tecca, Heather R., Molenaar, Remco J., Battiwalla, Minoo, Savani, Bipin N., Flowers, Mary E. D., Cooke, Kenneth R., Hamilton, Betty K., Kalaycio, Matt, Maciejewski, Jaroslaw P., Ahmed, Ibrahim, Akpek, Gorgun, Bajel, Ashish, Buchbinder, David, Cahn, Jean-Yves, D'Souza, Anita, Daly, Andrew, DeFilipp, Zachariah, Ganguly, Siddhartha, Hamadani, Mehdi, Hayashi, Robert J., Hematti, Peiman, Inamoto, Yoshihiro, Khera, Nandita, Kindwall-Keller, Tamila, Landau, Heather, Lazarus, Hillard, Majhail, Navneet S., Marks, David I., Olsson, Richard F., Seo, Sachiko, Steinberg, Amir, William, Basem M., Wirk, Baldeep, Yared, Jean A., Aljurf, Mahmoud, Abidi, Muneer H., Allewelt, Heather, Beitinjaneh, Amer, Cook, Rachel, Cornell, Robert F., Fay, Joseph W., Hale, Gregory, Chakrabarty, Jennifer Holter, Jodele, Sonata, Kasow, Kimberly A., Mahindra, Anuj, Malone, Adriana K., Popat, Uday, Rizzo, J. Douglas, Schouten, Harry C., Warwick, Anne B., Wood, William A., Sekeres, Mikkael A., Litzow, Mark R., Gale, Robert P., Hashmi, Shahrukh K., Radivoyevitch, Tomas, Dean, Robert M., Shaw, Bronwen E., Brazauskas, Ruta, Tecca, Heather R., Molenaar, Remco J., Battiwalla, Minoo, Savani, Bipin N., Flowers, Mary E. D., Cooke, Kenneth R., Hamilton, Betty K., Kalaycio, Matt, Maciejewski, Jaroslaw P., Ahmed, Ibrahim, Akpek, Gorgun, Bajel, Ashish, Buchbinder, David, Cahn, Jean-Yves, D'Souza, Anita, Daly, Andrew, DeFilipp, Zachariah, Ganguly, Siddhartha, Hamadani, Mehdi, Hayashi, Robert J., Hematti, Peiman, Inamoto, Yoshihiro, Khera, Nandita, Kindwall-Keller, Tamila, Landau, Heather, Lazarus, Hillard, Majhail, Navneet S., Marks, David I., Olsson, Richard F., Seo, Sachiko, Steinberg, Amir, William, Basem M., Wirk, Baldeep, Yared, Jean A., Aljurf, Mahmoud, Abidi, Muneer H., Allewelt, Heather, Beitinjaneh, Amer, Cook, Rachel, Cornell, Robert F., Fay, Joseph W., Hale, Gregory, Chakrabarty, Jennifer Holter, Jodele, Sonata, Kasow, Kimberly A., Mahindra, Anuj, Malone, Adriana K., Popat, Uday, Rizzo, J. Douglas, Schouten, Harry C., Warwick, Anne B., Wood, William A., Sekeres, Mikkael A., Litzow, Mark R., Gale, Robert P., and Hashmi, Shahrukh K.

Abstract

Background: Exposures to DNA-damaging drugs and ionizing radiations increase risks of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Methods: 9028 recipients of hematopoietic cell autotransplants (1995-2010) for Hodgkin lymphoma (HL; n=916), non-Hodgkin lymphoma (NHL; n=3546) and plasma cell myeloma (PCM; n=4566), reported to the CIBMTR, were analyzed for risk of subsequent AML or MDS. Results: 335 MDS/ AML cases were diagnosed posttransplant (3.7%). Variables associated with an increased risk for AML or MDS in multivariate analyses were: (1) conditioning with total body radiation versus chemotherapy alone for HL (HR=4.0; 95% confidence interval [1.4, 11.6]) and NHL (HR=2.5 [1.1, 2.5]); (2) >= 3 versus 1 line of chemotherapy for NHL (HR=1.9 [1.3, 2.8]); and (3) subjects with NHL transplanted in 2005-2010 versus 1995-1999 (HR=2.1 [1.5, 3.1]). Using Surveillance, Epidemiology and End Results (SEER) data, we found risks for AML/ MDS in HL, NHL and PCM to be 5-10 times the background rate. In contrast, relative risks were 10-50 for AML and approximately 100 for MDS in the autotransplant cohort. Conclusions: There are substantial risks of AML and MDS after autotransplants for HL, NHL and PCM.

Published
2018
Full Text
View/download PDF

36. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia

Author

Kebriaei, Partow, primary, Anasetti, Claudio, additional, Zhang, Mei-Jie, additional, Wang, Hai-Lin, additional, Aldoss, Ibrahim, additional, de Lima, Marcos, additional, Khoury, H. Jean, additional, Sandmaier, Brenda M., additional, Horowitz, Mary M., additional, Artz, Andrew, additional, Bejanyan, Nelli, additional, Ciurea, Stefan, additional, Lazarus, Hillard M., additional, Gale, Robert Peter, additional, Litzow, Mark, additional, Bredeson, Christopher, additional, Seftel, Matthew D., additional, Pulsipher, Michael A., additional, Boelens, Jaap-Jan, additional, Alvarnas, Joseph, additional, Champlin, Richard, additional, Forman, Stephen, additional, Pullarkat, Vinod, additional, Weisdorf, Daniel, additional, Marks, David I., additional, Hogan, William, additional, Battiwalla, Minoo, additional, Copelan, Edward, additional, Hildebrandt, Gerhard, additional, Ganguly, Sid, additional, Majhail, Navneet, additional, Woolfrey, Ann, additional, Nivison-Smith, Ian, additional, Hertzberg, Mark, additional, Diaz, Miguel Angel, additional, Jakubowski, Ann, additional, Ustun, Celalettin, additional, Yong, Agnes, additional, Freytes, Cesar, additional, DeFilipp, Zachariah, additional, Inamoto, Yoshi, additional, Cahn, Jean-Yves, additional, Savani, Bipin, additional, Yared, Jean, additional, Bajel, Ashish, additional, Bacher, Ulrike, additional, Uy, Geoffrey, additional, Rizzieri, David, additional, Wieduwilt, Matthew, additional, Schultz, Kirk, additional, Grunwald, Michael, additional, Kamble, Rammurti, additional, Qayed, Muna, additional, Brammer, Jonathan, additional, Ballen, Karen, additional, Khera, Nandita, additional, Schouten, Harry, additional, Bierings, Marc, additional, Kanakry, Christopher, additional, Wood, William Allen, additional, Saad, Ayman, additional, Savoie, Lynn, additional, Hamilton, Betty Ky, additional, Aljurf, Mahmoud, additional, Vij, Ravi, additional, Pawarode, Attaphol, additional, Olsson, Richard, additional, Wirk, B. Mona, additional, Beitinjaneh, Amer, additional, Seo, Sachiko, additional, Cerny, Jan, additional, Akpek, Gorgun, additional, Norkin, Maxim, additional, Nishihori, Taiga, additional, Lazaryan, Aleksandr, additional, and Sabloff, Mitchell, additional

Published
2018
Full Text
View/download PDF

37. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age

Author

Vrooman, Lynda M., Millard, Heather R., Brazauskas, Ruta, Majhail, Navneet S., Battiwalla, Minoo, Flowers, Mary E., Savani, Bipin N., Akpek, Gorgun, Aljurf, Mahmoud, Bajwa, Rajinder, Baker, K. Scott, Beitinjaneh, Amer, Bitan, Menachem, Buchbinder, David, Chow, Eric, Dandoy, Christopher, Dietz, Andrew C., Diller, Lisa, Gale, Robert Peter, Hashmi, Shahrukh K., Hayashi, Roberti, Hematti, Peiman, Kamble, Rammurti T. f, Kasow, Kimberly A., Kletzel, Morris, Lazarus, Hillard M., Malone, Adriana K., Marks, David I., O'Brien, Tracey A., Olsson, Richard, Ringden, Olle, Seo, Sachiko, Steinberg, Amir, Yu, Lolie C., Warwick, Anne, Shaw, Bronwen, Duncan, Christine, Vrooman, Lynda M., Millard, Heather R., Brazauskas, Ruta, Majhail, Navneet S., Battiwalla, Minoo, Flowers, Mary E., Savani, Bipin N., Akpek, Gorgun, Aljurf, Mahmoud, Bajwa, Rajinder, Baker, K. Scott, Beitinjaneh, Amer, Bitan, Menachem, Buchbinder, David, Chow, Eric, Dandoy, Christopher, Dietz, Andrew C., Diller, Lisa, Gale, Robert Peter, Hashmi, Shahrukh K., Hayashi, Roberti, Hematti, Peiman, Kamble, Rammurti T. f, Kasow, Kimberly A., Kletzel, Morris, Lazarus, Hillard M., Malone, Adriana K., Marks, David I., O'Brien, Tracey A., Olsson, Richard, Ringden, Olle, Seo, Sachiko, Steinberg, Amir, Yu, Lolie C., Warwick, Anne, Shaw, Bronwen, and Duncan, Christine

Abstract

Very young children undergoing hematopoietic cell transplantation (HCT) are a unique and vulnerable population. We analyzed outcomes of 717 patients from 117 centers who survived relapse free for year after allogeneic myeloablative HCT for hematologic malignancy at <3 years of age, between 1987 and 2012. The median follow-up was 8.3 years (range, 1.0 to 26.4 years); median age at follow-up was 9 years (range, 2 to 29 years). Ten-year overall and relapse-free survival were 87% (95% confidence interval [CI], 85% to 90%) and 84% (95% CI, 81% to 87%). Ten-year cumulative incidence of relapse was 11% (95% CI, 9% to 13%). Of 84 deaths, relapse was the leading cause (43%). Chronic graft-versus-host-disease 1 year after HCT was associated with increased risk of mortality (hazard ratio [HR], 2.1; 95% CI, 1.3 to 3.3; P=.0018). Thirty percent of patients experienced >= 1 organ toxicity/late effect >1 year after HCT. The most frequent late effects included growth hormone deficiency/growth disturbance (10-year cumulative incidence, 23%; 95% CI, 19% to 28%), cataracts (18%; 95% CI, 15% to 22%), hypothyroidism (13%; 95% CI, 10% to 16%), gonadal dysfunction/infertility requiring hormone replacement (3%; 95% CI, 2% to 5%), and stroke/seizure (3%; 95% CI, 2% to 5%). Subsequent malignancy was reported in 3.6%. In multivariable analysis, total body irradiation (TBI) was predictive of increased risk of cataracts (HR, 17.2; 95% CI, 7.4 to 39.8; P <.001), growth deficiency (HR, 3.5; 95% CI, 2.2 to 5.5; P <.001), and hypothyroidism (HR, 5.3; 95% CI, 3.0 to 9.4; P <.001). In summary, those who survived relapse free year after HCT for hematologic malignancy at <3 years of age had favorable overall survival. Chronic graft-versus host-disease and TBI were associated with adverse outcomes. Future efforts should focus on reducing the risk of relapse and late effects after HCT at early age.

Published
2017
Full Text
View/download PDF

38. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma

Author

Cornell, Robert F, D'Souza, Anita, Kassim, Adetola A, Costa, Luciano J, Innis-Shelton, Racquel D, Zhang, Mei-Jie, Huang, Jiaxing, Abidi, Muneer, Aiello, Jack, Akpek, Gorgun, Bashey, Asad, Bashir, Qaiser, Cerny, Jan, Comenzo, Raymond, Diaz, Miguel Angel, Freytes, César, Gale, Robert Peter, Ganguly, Siddhartha, Hamadani, Mehdi, Hashmi, Shahrukh, Holmberg, Leona, Hossain, Nasheed, Kamble, Rammurti T, Kharfan-Dabaja, Mohamed, Kindwall-Keller, Tamila, Kyle, Robert, Kumar, Shaji, Lazarus, Hillard, Lee, Cindy, Maiolino, Angelo, Marks, David I, Meehan, Kenneth, Mikhael, Joe, Nath, Rajneesh, Nishihori, Taiga, Olsson, Richard F., Ramanathan, Muthalagu, Saad, Ayman, Seo, Sachiko, Usmani, Saad, Vesole, David, Vij, Ravi, Vogl, Dan, Wirk, Baldeep M, Yared, Jean, Krishnan, Amrita, Mark, Tomer, Nieto, Yago, Hari, Parameswaran, Cornell, Robert F, D'Souza, Anita, Kassim, Adetola A, Costa, Luciano J, Innis-Shelton, Racquel D, Zhang, Mei-Jie, Huang, Jiaxing, Abidi, Muneer, Aiello, Jack, Akpek, Gorgun, Bashey, Asad, Bashir, Qaiser, Cerny, Jan, Comenzo, Raymond, Diaz, Miguel Angel, Freytes, César, Gale, Robert Peter, Ganguly, Siddhartha, Hamadani, Mehdi, Hashmi, Shahrukh, Holmberg, Leona, Hossain, Nasheed, Kamble, Rammurti T, Kharfan-Dabaja, Mohamed, Kindwall-Keller, Tamila, Kyle, Robert, Kumar, Shaji, Lazarus, Hillard, Lee, Cindy, Maiolino, Angelo, Marks, David I, Meehan, Kenneth, Mikhael, Joe, Nath, Rajneesh, Nishihori, Taiga, Olsson, Richard F., Ramanathan, Muthalagu, Saad, Ayman, Seo, Sachiko, Usmani, Saad, Vesole, David, Vij, Ravi, Vogl, Dan, Wirk, Baldeep M, Yared, Jean, Krishnan, Amrita, Mark, Tomer, Nieto, Yago, and Hari, Parameswaran

Abstract

Bortezomib (V), lenalidomide (R), cyclophosphamide (C), and dexamethasone (D) are components of the most commonly used modern doublet (RD, VD) or triplet (VRD, CVD) initial induction regimens before autologous hematopoietic cell transplantation (AHCT) for multiple myeloma (MM) in the United States. In this study we evaluated 693 patients receiving "upfront" AHCT after initial induction therapy with modern doublet or triplet regimens using data reported to the Center for International Blood and Marrow Transplant Research from 2008 to 2013. Analysis was limited to those receiving a single AHCT after 1 line of induction therapy within 12 months from treatment initiation for MM. In multivariate analysis, progression-free survival (PFS) and overall survival were similar irrespective of induction regimen. However, high-risk cytogenetics and nonreceipt of post-transplant maintenance/consolidation therapy were associated with higher risk of relapse. Patients receiving post-transplant therapy had significantly improved 3-year PFS versus no post-transplant therapy (55% versus 39%, P = .0001). This benefit was most evident in patients not achieving at least a complete response post-AHCT (P = .005). In patients receiving upfront AHCT, the choice of induction regimen (doublet or triplet therapies) appears to be of lower impact than use of post-transplant therapy.

Published
2017
Full Text
View/download PDF

39. Successful Early Outcome with Low-Dose (400 cGY) Total Body Irradiation in Combination with Busulfan and Fludarabine Myeloablative Conditioning Followed By Matched Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation in a Patient with Non-Remission Acute Myelogeneous Leukemia with Diffuse Extramedullary Disease in Multiple Sites

Author

Akpek, Gorgun, primary, Nathan, Sunita, additional, Maciejewski, John J., additional, Katz, Deborah A., additional, Echeverria, Ashley, additional, Hodges, Lindsay, additional, Diaz, Aidnag Z., additional, and Abrams, Ross Allen, additional

Published
2016
Full Text
View/download PDF

42. Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial

Author

Makowski, Mat, primary, Ahmed, Elshafa, additional, Schlotter, Sarah, additional, Pearson, Rebecca, additional, Kitzler, Rhonda, additional, Alvarnas, Joseph C., additional, Le Rademacher, Jennifer, additional, Wang, Yanli, additional, Little, Richard F, additional, Akpek, Gorgun, additional, Ayala, Ernesto, additional, Devine, Steven M., additional, Kaplan, Lawrence D., additional, Noy, Ariela, additional, Popat, Uday R., additional, Hsu, Jack W, additional, Morris, Lawrence E., additional, Thompson, Jason, additional, Horowitz, Mary H, additional, Mendizabal, Adam M., additional, Levine, Alexandra M., additional, Krishnan, Amrita, additional, Hade, Erinn, additional, Hofmeister, Craig C, additional, Forman, Stephen J., additional, Navarro, Willis H., additional, Ambinder, Richard F., additional, Lozanski, Gerard, additional, and Baiocchi, Robert A, additional

Published
2016
Full Text
View/download PDF

43. An Analysis of the Effect of Race, Socioeconomic Status and Center Size on Unrelated NMDP Donor Outcomes: Donor Toxicities are More Common at Low Volume Bone Marrow Collection Centers

Author

Shaw, Bronwen E., Logan, Brent R., Kiefer, Deidre M., Chitphakdithai, Pintip, Pedersen, Tanya L., Abdel-Azim, Hisham, Abidi, Muneer H., Akpek, Gorgun, Diaz, Miguel A., Artz, Andrew S., Dandoy, Christopher, Gajewski, James L., Hematti, Peiman, Kamble, Rammurti T., Kasow, Kimberley A., Lazarus, Hillard M., Liesveld, Jane L., Majhail, Navneet S., O’Donnell, Paul V., Olsson, Richard F., Savani, Bipin N., Schears, Raquel M., Stroncek, David F., Switzer, Galen E., Williams, Eric P., Wingard, John R., Wirk, Baldeep M., Confer, Dennis L., and Pulsipher, Michael A.

Subjects
Adult, Male, Peripheral Blood Stem Cell Transplantation, Hospitals, Low-Volume, Adolescent, Filgrastim, Racial Groups, Pain, Middle Aged, Article, Tissue Donors, Blood Cell Count, Body Mass Index, Young Adult, Social Class, Cytomegalovirus Infections, Income, Tissue and Organ Harvesting, Humans, Anesthesia, Female, Hospitals, High-Volume, Bone Marrow Transplantation
Abstract

Previous studies have shown that risks of collection-related pain and symptoms are associated with sex, body mass index (BMI), and age in unrelated donors undergoing collection at National Marrow Donor Program (NMDP) centers. We hypothesized that other important factors (race, socioeconomic status (SES), and number of procedures at the collection center) might affect symptoms in donors. We assessed outcomes in 2,726 bone marrow (BM) and 6,768 peripheral blood stem cell (PBSC) donors collected between 2004 and 2009. Pain/symptoms are reported as maximum levels over mobilization and collection (PBSC) or within 2 days of collection (BM) and at 1 week after collection. For PBSC donors, race and center volumes were not associated with differences in pain/symptoms at any time. PBSC donors with high SES levels reported higher maximum symptom levels 1 week post donation (p=0.017). For BM donors, black males reported significantly higher levels of pain (OR=1.90, CI=1.14-3.19, p=0.015). No differences were noted by SES groups. BM donors from low volume centers reported more toxicity (OR=2.09, CI=1.26-3.46, p=0.006). In conclusion, race and SES have a minimal effect on donation associated symptoms. However, donors from centers performing ≤1 BM collection every 2 months have more symptoms following BM donation. Approaches should be developed by registries and low volume centers to address this issue.

Published
2015

45. The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes

Author

Artz, Andrew S., primary, Logan, Brent, additional, Zhu, Xiaochun, additional, Akpek, Gorgun, additional, Bufarull, Rodrigo Martino, additional, Gupta, Vikas, additional, Lazarus, Hillard M., additional, Litzow, Mark, additional, Loren, Alison, additional, Majhail, Navneet S., additional, Maziarz, Richard T., additional, McCarthy, Philip, additional, Popat, Uday, additional, Saber, Wael, additional, Spellman, Stephen, additional, Ringden, Olle, additional, Wickrema, Amittha, additional, Pasquini, Marcelo C., additional, and Cooke, Kenneth R., additional

Published
2016
Full Text
View/download PDF

46. A Concise Update on Chronic Graft Versus Host Disease

Author

Akpek, Gorgun

Subjects
Graft versus host reaction -- Physiological aspects -- Prevention -- Prognosis -- Care and treatment -- Complications and side effects, Stem cells -- Transplantation, Health
Abstract

Byline: Gorgun Akpek, MD, MHS The cumulative incidence of chronic graft versus host disease (GVHD) has increased dramatically over the past decade because of the change in stem cell transplantation [...]

Published
2006

47. HLA DR15 Antigen Status Does Not Impact Graft-versus-Host Disease or Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies

Author

Battiwalla, Minoo, Ellis, Kristin, Li, Peigang, Pavletic, Steven Z., Akpek, Gorgun, Hematti, Peiman, Klumpp, Thomas R., Maziarz, Richard T., Savani, Bipin N., Aljurf, Mahmoud D., Cairo, Mitchell S., Drobyski, William R., George, Biju, Hahn, Theresa, Khera, Nandita, Litzow, Mark R., Loren, Alison W., Saber, Wael, Arora, Mukta, Urbano-Ispizua, Alvaro, Cutler, Corey, Flowers, Mary E.D., and Spellman, Stephen R.

Published
2012
Full Text
View/download PDF

48. Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

Author

Rapoport, Aaron P., primary, Aqui, Nicole A., additional, Stadtmauer, Edward A., additional, Vogl, Dan T., additional, Xu, Yin Yan, additional, Kalos, Michael, additional, Cai, Ling, additional, Fang, Hong-Bin, additional, Weiss, Brendan M., additional, Badros, Ashraf, additional, Yanovich, Saul, additional, Akpek, Gorgun, additional, Tsao, Patricia, additional, Cross, Alan, additional, Mann, Dean, additional, Philip, Sunita, additional, Kerr, Naseem, additional, Brennan, Andrea, additional, Zheng, Zhaohui, additional, Ruehle, Kathleen, additional, Milliron, Todd, additional, Strome, Scott E., additional, Salazar, Andres M., additional, Levine, Bruce L., additional, and June, Carl H., additional

Published
2014
Full Text
View/download PDF

49. Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR In Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated With Encouraging Post Auto-SCT Responses

Author

Rapoport, Aaron P., primary, Stadtmauer, Edward A., additional, Vogl, Dan T., additional, Weiss, Brendan M, additional, Binder-Scholl, Gwendolyn K., additional, Smethurst, Dominic P., additional, Finklestein, Jeffrey, additional, Kulikovskaya, Irina, additional, Gupta, Minnal, additional, Brewer, Joanna E., additional, Bennett, Alan D., additional, Gerry, Andrew B., additional, Pumphrey, Nicholas J., additional, Tayton-Martin, Helen K., additional, Ribeiro, Lilliam C., additional, Badros, Ashraf, additional, Yanovich, Saul, additional, Akpek, Gorgun, additional, Kerr, Naseem, additional, Philip, Sunita, additional, Westphal, Sandra, additional, Levine, Bruce L., additional, Jakobsen, Bent K., additional, Kalos, Michael, additional, and June, Carl H., additional

Published
2013
Full Text
View/download PDF

50. Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT

Author

Rapoport, Aaron P, primary, Stadtmauer, Edward A, additional, Vogl, Dan T, additional, Weiss, Brendan, additional, Binder-Scholl, Gwendolyn K, additional, Smethurst, Dominic P, additional, Finklestein, Jeffrey, additional, Kulikovskaya, Irina, additional, Gupta, Minnal, additional, Brewer, Joanna E, additional, Bennett, Alan D, additional, Gerry, Andrew B, additional, Pumphrey, Nick J, additional, Tayton-Martin, Helen K, additional, Ribeiro, Lilliam, additional, Badros, Ashraf Z, additional, Yanovich, Saul, additional, Akpek, Gorgun, additional, Kerr, Naseem, additional, Philip, Sunita, additional, Westphal, Sandra, additional, Bruce, Levine L, additional, Jakobsen, Bent K, additional, June, Carl H, additional, and Kalos, Michael, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results